PIC1

PIC1 is an investigational in vivo CAR-T cell therapy developed by Chongqing Precision Biotech for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). Unlike traditional CAR-T therapies that require the ex vivo genetic modification of a patient's T cells, PIC1 is designed to generate CAR-T cells directly within the patient's body. The therapy utilizes a viral vector (likely lentiviral, as indicated by transducing units) to transduce endogenous T cells in vivo, directing them to express a chimeric antigen receptor (CAR) that targets B-cell specific antigens, typically CD19. This approach aims to streamline the treatment process by eliminating the need for complex cell manufacturing and potentially reducing the requirement for intensive lymphodepletion, offering a more accessible therapeutic option for patients with aggressive B-cell malignancies.

Other names

PIC1 InjectionPIC-1 InjectionPIC 1 Injection